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Abstract
Background—Recent literature documents a stronger association between nonfasting triglycerides
(TG) and cardiovascular risk compared to fasting TG. Given concerns over antipsychotic effects on
serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia
Trial.
Methods—Change in nonfasting TG, adjusted for baseline value, was compared between
antipsychotic treatment groups using subjects with nonfasting laboratory assessments at baseline and
3 months.
Results—Among the 246 subjects there were significant treatment differences in 3-month change
from baseline (p=0.009). The greatest increases in median and adjusted mean nonfasting TG levels
were seen among those randomized to quetiapine (mean +54.7 mg/dl, median +26 mg/dl) and
olanzapine (mean +23.4 mg/dl, median +26.5 mg/dl), while ziprasidone was neutral (mean +0.0 mg/
dl, median + 8 mg/dl), and decreases were seen with risperidone (mean −18.4 mg/dl, median −6.5
mg/dl) and perphenazine (mean −1.3 mg/dl, median −22 mg/dl). Pairwise comparisons indicated a
significant between-group difference for perphenazine vs. olanzapine (p=0.002) and a trend for
perphenazine vs. quetiapine (p=0.006).
Conclusions—This analysis provides further evidence for differential antipsychotic metabolic
liabilities, and confirms signals for the effects of olanzapine and quetiapine on serum TG seen in
earlier CATIE analyses. Future consensus recommendations will clarify the role of nonfasting TG
monitoring in routine clinical practice.
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Introduction
Fasting triglyceride (TG) values are a marker of insulin resistance, and moderate elevations
are associated with increased cardiovascular (CV) risk independent of high density lipoprotein
cholesterol levels (Jeppesen et al., 1998). However, there is evidence to indicate that
atherosclerosis may be a postprandial phenomenon in which atherogenic remnant lipoproteins
(chylomicrons and very low-density lipoproteins) play a critical role (Eberly et al., 2003). These
triglyceride-rich particles are smaller than other lipid components, and more readily penetrate
arterial intimal cells. Individuals are in a nonfasting state most of the day with respect to serum
TG, since fat tolerance testing notes that TG levels peak 4 hours after an oral fat load, and
return to basal values only after 8–10 hours (Nordestgaard et al., 2007).
Data from the Copenhagen study (n=13,981, mean follow-up 26 years), indicate a significant
linear correlation between nonfasting TG values and directly measured remnant lipoproteins
(Nordestgaard et al., 2007), providing the impetus to examine the association between
nonfasting TG and CV risk. Over the course of the study follow-up, there was a significant
relationship between nonfasting TG levels in men and women and risk of major CV-related
events including ischemic heart disease, myocardial infarction (MI), and mortality
(Nordestgaard et al., 2007). Compared to those with nonfasting TG < 1 mmol/l (88.5 mg/dl),
women and men with levels of 2–2.99 mmol/L (177.0–264.6 mg/dL) had adjusted hazard ratios
for MI of 2.5 and 1.6 respectively. The superiority of nonfasting TG over fasting TG is seen
in prospective data from the Women’s Health Study (n=26,509, median follow-up 11.4 years)
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(Bansal et al., 2007). While there was no relationship between increasing tertiles of fasting TG
values and risk of CV events in fully adjusted models, nonfasting TG tertiles were significantly
associated with CV risk, with TG levels measured 2–4 hours postprandially showing the
strongest association.
Schizophrenia patients are a high-risk group for CV mortality, with lifestyle factors and
treatment playing additive roles (Goff et al., 2005; Newcomer and Hennekens, 2007). Given
the differential impact of antipsychotics on fasting TG (Meyer et al., 2008) and random serum
TG levels (Lieberman et al., 2005) in the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) Schizophrenia Trial phase 1, the a priori hypothesis for this analysis
is that there would be significant between-drug differences for nonfasting TG changes.
Methods
The recruitment criteria for the CATIE Schizophrenia Trial and enrollment methods have been
previously described (Lieberman et al., 2005). CATIE subjects were asked to present in a
fasting state for laboratory evaluations, but there was a significant range recorded for time since
last meal. Only subjects who ate < 8 hours prior to phlebotomy at the baseline and 3 month
assessment were used for this analysis. The 3-month time point was chosen to maximize subject
retention, while providing a physiologically meaningful time frame to assess the impact of
antipsychotic treatment. Due to the skewness of the nonfasting TG data, treatment groups were
compared with a nonparametric test, rank analysis of covariance (Koch et al., 1982). Multiple
factors were examined to assess the influence on outcome (age, gender, race/ethnicity, smoking
status, baseline antipsychotic medication, baseline nonfasting TG), and treatment group
comparisons were adjusted for those factors that were statistically significant (p<0.05). A
supportive unadjusted Kruskal Wallis rank test was also performed. In both analyses, if the
overall 4 df test for treatment group was significant at 0.05, then the 10 between-drug
comparisons were evaluated using a Bonferroni correction, yielding an alpha of 0.05/10 =
0.005. Due to the relatively conservative nature of this correction, p-values between 0.005 and
0.01 are also identified for the reader’s discretion. All metabolic laboratory measures were
performed at the Quintiles central laboratory.
Results
Demographic comparison between subjects with nonfasting TG at both time points (n=246)
and other subjects with baseline and 3-month data (n=687) showed similar distributions by
gender, ethnicity, body mass index, diabetes mellitus and smoking prevalence, but the
nonfasting TG cohort was older by 2.6 years, with 2.3 years longer drug exposure, and had
fewer white subjects (Table 1). At study entry, 28.1% of the 246 subjects were on no
antipsychotic, 19.1% on olanzapine, 4.9% on quetiapine, 19.5% on risperidone, 17.5% on other
antipsychotics, and 11.0% on antipsychotic combinations. The distribution of median
nonfasting TG is comparable to general population studies (Nordestgaard et al., 2007), and
shows serum values peaking 2–4 hours from last meal, with the numerically highest peak seen
in subjects reporting last meal 2–3 hours prior to laboratory determination (Figure 1).
Among the demographic factors examined, only baseline nonfasting TG values were
significantly associated with 3-month changes in this variable, and this was utilized in adjusted
analyses. Table 2 presents median, and baseline-adjusted mean 3-month nonfasting TG
changes, although all statistical testing is nonparametric (rank transformation) due to the
skewness of the data. The greatest increases in median and adjusted mean nonfasting TG levels
were seen among those randomized to quetiapine (mean +54.7 mg/dl, median +26 mg/dl) and
olanzapine (mean +23.4 mg/dl, median +26.5 mg/dl), while ziprasidone was neutral (mean
+0.0 mg/dl, median + 8 mg/dl), and decreases were seen in subjects exposed to risperidone
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(mean −18.4 mg/dl, median −6.5 mg/dl) and perphenazine (mean −1.3 mg/dl, median −22 mg/
dl). Adjustment for baseline nonfasting TG values with a ranked ANCOVA revealed overall
significant treatment differences (p=0.009), with a significant between-group difference for
perphenazine vs. olanzapine (p=0.002). The change in nonfasting TG was also numerically
different for perphenazine vs. quetiapine, although not statistically significant with the
Bonferroni correction (p=0.006). A supportive unadjusted analysis was similar: p=0.016
overall, p=0.002 for perphenazine vs. olanzapine, and p=0.012 for perphenazine vs. quetiapine.
For phase 1, there was a distinct possibility that subjects could be randomized to the same
medication taken at study baseline, and be unlikely to experience significant changes in
outcome measures compared to those who switched medications. Among the 246 subjects,
there were 37 nonswitchers (13 olanzapine, 14 risperidone, 8 quetiapine, 2 other), so the data
were reexamined after excluding these subjects (Table 3). In this analysis, the between-drug
treatment differences at 3 months became more pronounced (p=0.001, adjusted for baseline).
The pairwise comparisons now revealed significant differences for olanzapine vs.
perphenazine (p<0.001), olanzapine vs. risperidone (p=0.002), and quetiapine vs. perphenazine
(p=0.003). Unadjusted results were similar (overall p=0.001). Due to the small number of
nonswitchers, and the unbalanced composition (predominantly olanzapine and risperidone at
baseline), comparisons of switchers vs. nonswitchers were not performed.
Discussion
Presented here are the first data to examine the impact of antipsychotic therapy specifically in
subjects with nonfasting serum TG values. The concept that postprandial hyperlipidemia best
reflects the role of triglyceride-rich particles in atherogenesis is quite new, and has only recently
been born out by large, long-term clinical trials (Eberly et al., 2003; Bansal et al., 2007;
Nordestgaard et al., 2007). Most studies of antipsychotic lipid effects have focused on fasting
TG values (Meyer and Koro, 2004), and rightfully so, due to the association between fasting
TG and the metabolic syndrome (McEvoy et al., 2005) or directly measured insulin sensitivity
(McLaughlin et al., 2003).
Olanzapine treatment has been associated with deleterious impact on lipid profiles (Meyer and
Koro, 2004), but recent findings from a large first-episode trial (McEvoy et al., 2007) and
CATIE phase 1 raised concerns that, at dosages used to treat schizophrenia, quetiapine is also
associated with significant increases in random TG (Lieberman et al., 2005; Correll, 2007) and
fasting TG (McEvoy et al., 2007; Meyer et al., 2008). With the stringent Bonferroni correction,
the quetiapine vs. perphenazine comparison (p=0.006) did not meet the required 0.005 level
of significance, but the numerical change in nonfasting TG seen in the adjusted analysis (+54.7
mg/dl), and the significant result when nonswitchers were excluded (quetiapine vs.
perphenazine p=0.003), suggests that quetiapine has a lipid profile distinct from risperidone
(−18.4 mg/dl) in a manner not appreciated several years ago, when the American Diabetes
Association/American Psychiatric Association consensus paper on antipsychotic metabolic
effects found these agents comparable on the basis of the available data (American Diabetes
Association, 2004). That ziprasidone, risperidone and perphenazine treatment did not
significantly increase nonfasting TG was expected, although it is surprising that ziprasidone
in particular did not decrease nonfasting TG.
One limitation of this study is that the small sample size of each drug arm precludes
stratification by time since last meal, age, gender or race. These effects can be managed with
controlled prospective studies using fat tolerance testing or other means to examine lipid
metabolism. The findings from the recent large clinical trials (Nordestgaard et al., 2007; Bansal
et al., 2007) demonstrate a robust association between nonfasting TG and CV risk. Whether
nonfasting TG will replace fasting TG measurements, or used in addition to fasting TG to
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provide added information on CV risk, and the optimal time since last meal to obtain this result,
awaits consensus recommendations. Nonetheless, this study provides confirmation of the
differential metabolic impact of atypical antipsychotics, and the need for clinicians to routinely
monitor parameters associated with metabolic risk.
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Median Baseline Nonfasting Triglyceride (TG) Values By Time Since Last Meal
* IQ = Interquartile Range 25th – 75th Percentile
Meyer et al. Page 7

























Meyer et al. Page 8
Table 1
Demographic Comparison of CATIE Subjects With Nonfasting Triglyceride Levels at Both Baseline and 3-Month
Assessments vs. Other Subjects With Baseline and 3-Month Data
Parameter Nonfasting TG Other Subjects p*















































Table entries are Mean ± SD, or %.
*
P values for comparison of means are from a t-test; those for comparison of proportions are from a chi-square test with 1 df. NS = not significant (p≥0.05)
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Table 2
3-Month Changes From Baseline in Nonfasting Triglycerides (mg/dl) by Treatment Group
Observed Adjusted†
N Median (Interquartile Range) Mean ± SD Least Squares Mean ± SE
OLANZAPINE 62 26.5 (−20 – 80) 33.1 ± 159.1 23.4 ± 22.8
PERPHENAZINE 39 −22 (−81 – 24) −3.7 ± 243.8 −1.3 ± 28.6
QUETIAPINE 59 26 (−34 – 96) 36.0 ± 264.0 54.7 ± 23.5
RISPERIDONE 56 −6.5 (−52 – 38) −7.9 ± 85.3 −18.4 ± 24.0
ZIPRASIDONE 30 8 (−48 – 58) 0.4 ± 145.0 0.0 ± 32.7
Overall Treatment Difference 0.016 * 0.009 **
†
Model adjusted for baseline triglycerides. Age, gender, race, ethnicity, baseline antipsychotic medication and smoking were allowed to enter the model
but were not significant. The interaction between baseline triglycerides and treatment was also explored and was not significant.
*
Unadjusted comparisons using the Kruskal-Wallis rank test revealed overall significant treatment differences (p=0.016). Individual pairwise comparisons
revealed a significant difference for olanzapine vs. perphenazine (p=0.002).
**
Rank ANCOVA adjusting for baseline triglycerides revealed overall significant treatment differences (p=0.009). Individual pairwise comparisons
revealed a significant difference for perphenazine vs. olanzapine (p=0.002). The change in nonfasting TG was also numerically different for perphenazine
vs. quetiapine, although not statistically significant with the Bonferroni correction (p=0.006).
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Table 3
3-Month Changes From Baseline in Nonfasting Triglycerides (mg/dl) by Treatment Group Excluding Nonswitchers
Observed Adjusted†
N Median (Interquartile Range) Mean ± SD Least Squares Mean ± SE
OLANZAPINE 49 30 (−4 – 87) 64.3 ± 137.3 61.5 ± 24.0
PERPHENAZINE 39 −22 (−81 – 24) −3.7 ± 243.8 −2.4 ± 26.7
QUETIAPINE 51 27 (−32 – 96) 57.5 ± 179.6 59.8 ± 23.5
RISPERIDONE 42 −10.5 (−76 – 31) −12.2 ± 79.8 −13.1 ± 25.7
ZIPRASIDONE 28 8 (−64 – 56) 2.0 ± 149.6 −1.8 ± 31.5
Overall Treatment Difference 0.001* 0.001**
†
Model adjusted for baseline triglycerides. Age, gender, race, ethnicity, baseline antipsychotic medication and smoking were allowed to enter the model
but were not significant. The interaction between baseline triglycerides and treatment was also explored and was not significant.
*
Unadjusted comparisons using the Kruskal-Wallis rank test revealed overall significant treatment differences (p=0.001). Individual pairwise comparisons
revealed a significant difference for olanzapine vs. both perphenazine (p<0.001) and risperidone (p=0.001). The change in nonfasting TG was also
numerically different for perphenazine vs. quetiapine, although not statistically significant with the Bonferroni correction (p=0.008).
**
Rank ANCOVA adjusting for baseline triglycerides revealed overall significant treatment differences (p=0.001). Individual pairwise comparisons
revealed a significant difference for olanzapine vs. both perphenazine (p<0.001) and risperidone (p=0.002), and quetiapine vs. perphenazine (p=0.003).
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